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Drugs
Environment
Do Pharmaceutical Take-Back 
Programs Make a Difference?
in the
The state of Maine experimented with drugs 
last year. The state had already tested several methods 
for collecting unused pharmaceuticals, with varying degrees of 
success. After tracking surprisingly high concentrations of phar-
maceuticals in landfill leachate  —raising the potential for eventual 
ground and surface water contamination—the state decided to 
pursue a new tool to keep drugs out of the waste stream. Maine 
wanted to establish statewide collection programs, mandated   
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by legislation and paid for by manufac-
turers, that would intercept unwanted 
pharmaceutical products before they got 
to the trash. 
Although the state legislation bogged 
down earlier this year, other states have 
introduced bills similar to Maine’s, with 
some success. Meanwhile, Europe and 
Canada have had systems for pharma-
ceutical take-back programs in place 
for a decade or so. At the same time, an 
increasing number of reports from across 
the world have tracked active pharmaceu-
tical ingredients (APIs) in surface waters 
and even tap water, leading environmen-
tal scientists and water utilities to look for 
ways to limit the amount of drugs enter-
ing the environment.
The bulk of human pharmaceuticals 
found in waterways most likely got there 
by way of sewage. Taking unused pharma-
ceuticals out of landfills may make only 
a small difference in the concentrations 
of APIs found in water, say critics and 
supporters alike of such programs. But 
take-back programs may help prevent left-
over pharmaceuticals from being misused. 
For that reason and others, utilities and 
local governments are moving forward 
with a variety of pharmaceutical take-back 
efforts in the absence of regulations—or 
data indicating such programs actually 
work. 
Digging into the Trash
The  most  damning  evidence  yet  of 
human drugs’ impacts on wildlife comes 
from studies of fish. A study by Karen 
Kidd et al., in the 22 May 2007 issue of 
Proceedings of the National Academy of 
Sciences, showed the collapse of a popula-
tion of fish in an isolated lake spiked with 
relatively high levels of the synthetic estro-
gen 17α-ethinylestradiol. Other studies on 
aquatic populations in a waste-impacted 
stream in Boulder, Colorado, showed 
reproductive effects from estrogenic waste-
water effluent, according to Alan M. Vajda 
et al., writing in the 1 May 2008 issue of 
Environmental Science & Technology. 
Aside from any environmental implica-
tions, discarded pharmaceuticals pose the 
threat of misuse. “People will go to great 
lengths to reclaim a drug,” says Christian 
Daughton of the U.S. Environmental 
Protection Agency. He cites reports of “pee 
labs,” where a dealer might reclaim meth-
amphetamine from a user’s urine and recon-
stitute it for resale. But it’s not only drug 
users who go through the garbage for phar-
maceuticals, says Ann Pistell, an environ-
mental specialist at the Maine Department 
of Environmental Protection (DEP): “It’s 
accidental poisonings by children, pets, or 
wildlife who pluck them out.”
In January 2010, the Maine DEP 
meas  ured the concentrations of drugs in 
samples of leachate collected at three land-
fills, selected because they were receiving 
only household waste and not biosolids 
that might contain human-excreted drugs. 
DEP scientists were surprised to find what 
A 212  v o l u m e  118 | n u m b e r  5 | May 2010  •  Environmental Health Perspectives
Spheres of Influence | Drugs in the Environment
Save a Flush
O
nly certain drugs approved by the Food and Drug 
Admin  istration should be flushed down the toilet or 
drain. These include drugs deemed to be “especially 
harmful to a child, pet, or anyone else if taken accidentally,” 
according to the agency’s “Information for Consumers (Drugs)” 
webpage.
Once APIs reach the bacteria that clean up wastewater in 
treatment plants, drugs may degrade into daughter compounds 
that may be more or less toxic than the parent drug, or they 
may even return to their original forms. Some will flush out 
with treated effluent into streams, and some will be captured 
in biosolids—the sludge left over after water treatment—that 
might end up incinerated, spread over agricultural lands, or 
placed in landfills. A study by Dana Kolpin and colleagues in the 
15 March 2008 issue of Environmental Science & Technology 
found that earthworms from fields where biosolids had been 
spread as fertilizer had measurable amounts of pharmaceuticals 
in their bodies. 
Pharmaceuticals flushed into septic systems may pose even 
more of a threat to waterways than those put into municiple 
systems, according to some of the few studies on the topic. 
Conversely, study findings published in the February 2010 issue of 
Environmental Toxicology and Chemistry suggest that septic tanks 
may remove organic contaminants as effectively as wastewater 
treatment plants, although there are no data yet on specific drugs.  
could amount to yearly leachate emissions 
of hundreds of pounds of APIs from over-
the-counter and prescription drugs. “The 
fact that we found pharmaceuticals wasn’t a 
huge surprise, but the high levels were,” says 
Pistell. The pain reliever acetaminophen, 
for example, was present in samples from 
one landfill at concentrations of 117,000 
ng/L, the highest level of any drug meas-
ured in the study.
The prescription antibiotic cipro-
floxacin was present at concentrations 
of 269 ng/L, and lab tests even found 
cocaine—at  57  ng/L—in  one  land-
fill, according to the DEP’s unpublished 
findings. Other drugs found in all three 
landfills included low concentrations of 
estrone (from hormone replacement ther-
apy), albuterol (an asthma drug), and the 
antibiotic penicillin in the range of tens to 
hundreds parts per billion. 
The findings led the DEP to decide 
that disposing of unused pharmaceutical 
products in landfills—the current recom-
mendation of U.S. industry and govern-
ment to consumers wanting to clean out 
their medicine cabinets—is not a prudent 
or sustainable method of disposal. 
According to the SMARxT Disposal™ 
partnership, however, landfills are fine for 
disposal of pharmaceuticals. This partner-
ship of the U.S. Fish and Wildlife Service, 
the American Pharmacists Association, 
and the Pharmaceutical Research and 
Manufacturers of America recommends 
that medications be crushed and/or dis-
solved, mixed with kitty litter or other 
unappealing material (to discourage con-
sumption), then enclosed in a container or 
sealable baggie before disposal in the trash. 
The U.S. Office of National Drug Control 
Policy, in its 2009 “Proper Disposal of 
Prescription Drugs” factsheet, agrees with 
this advice where take-back programs are 
not available. Unused controlled drugs 
collected by law enforcement typically are 
incinerated—considered the most effective 
way to destroy APIs—through licensed 
medical waste collectors.
Susan Boehme, who studies contami-
nated coastal sediments with the Illinois–
Indiana Sea Grant program, says life-
cycle analyses of drug disposal methods 
are not yet complete. As someone who 
spends a lot of time helping communities 
set up and operate pharmaceutical take-
back programs, Boehme says she cautions 
stake  holders that the impacts of a local 
take-back program on pollution preven-
tion often will be unclear and that such 
programs are “definitely a precautionary 
approach.” 
Few studies have been conducted 
on  pharmaceuticals  in  landfills  and 
leachate, says Dana Kolpin of the U.S. 
Geological Survey, lead author of a land-
mark paper published 15 March 2002 in 
Environmental Science & Technology that 
showed the widespread presence of phar-
maceuticals in U.S. surface waters. Kolpin 
and his colleagues previously examined 
pharmaceuticals present in groundwater 
leachate plumes, and the team currently is 
attempting to organize a national survey 
of landfill leachate to better understand 
the levels of pharmaceuticals that may be 
present. Many landfill operations actually 
collect leachate for further treatment at a 
wastewater treatment plant, which may 
make this a slower pathway for drugs to 
travel into the environment, Kolpin says, 
“but it’s still a potential pathway.”
Kolpin adds, “At some point, somebody 
has to look and find the mass balance, 
so to speak.” How much of the pharma-
ceuticals in the environment, whether 
excreted or unused, come from residential 
waste versus hospitals versus farms? What 
sources are the biggest contributors? Not 
many answers exist to these questions at 
the moment, most researchers say. 
Filling in the Blanks
Currently, says Ilene Ruhoy of Touro 
University Nevada, take-back programs are 
“not standardized in any way.” Data collec-
tion from people turning in drugs may dif-
fer from event to event, as might methods 
used to classify them by type and measure 
the amount of drugs collected—for exam-
ple, whether that amount reflects the mass 
of the medication in its packaging, the mass 
of the complete formulated product (APIs 
plus excipients), or the mass of just the 
APIs. These differences make extrapolating 
data from an event to figure out its impact 
“really complicated,” she says, without even 
adding the complexities of the potential 
ecological effects of each drug.
Duane Huggett of the University of 
North Texas hopes to fill in some of the 
blanks on the exact benefits of take-back 
programs. For the City of Denton’s col-
lection in late April 2010, Huggett and 
his colleagues established a protocol for 
collecting drugs while logging statistically 
valid data for later evaluation. They hope 
to repeat this pilot program at future events 
across the United States. 
As more states roll out take-back leg-
islation and programs, the country could 
end up with 50 different state programs, 
Huggett says, and standardization, at least 
in data collection, would certainly help in 
assessing the impacts of these programs, 
if not their establishment and implemen-
tation.  Moreover,  without  regulation, 
some of these programs may not even be 
legal, according to Jen Jackson of East Bay 
Municipal Utility District, the public util-
ity serving San Francisco’s East Bay. For 
example, she says, until California set up its 
own guidance for water utilities and phar-
macies to collect unused pharmaceuticals, 
the state’s many take-back programs were 
operating in a legal gray zone. 
That’s in large part because pharma-
ceutical take-back programs are subject to 
the same rules that are meant to keep con-
trolled substances from reentering the sup-
ply chain either legally or illegally: under 
the federal Controlled Substances Act, the 
U.S. Drug Enforcement Administration 
requires controlled substances to be turned 
in to the proper law enforcement officials. 
Any collection program must be carefully 
monitored by law enforcement, Jackson 
says, so nothing is diverted from a col-
lection box, for example. The additional 
monitoring needed for these events can 
increase event expenses.
Jackson says pharmacies must be very 
careful to involve as few hands as possible 
in take-back programs. For instance, in 
California the public can deposit unused 
pharmaceuticals in one-way bins with two-
key systems. Collections of full bins might 
take place with a licensed medical waste 
hauler and a pharmacist present as wit-
nesses to ensure drugs in high demand 
on the street (such as the neurostimulant 
Ritalin and the analgesic Vicodin) are not 
diverted from their path to destruction. 
LD 821, the Maine bill introduced 
in March 2009 by Representative Anne 
Perry, would have required industry to 
assist in establishing take-back programs 
for unused pharmaceuticals in that state. 
The bill called for manufacturers to dem-
onstrate to the Maine DEP that they were 
taking part in or running their own take-
back programs, with proper disposal of 
their products through hazardous waste 
incinerators. The bill also called for phar-
macies to provide prepaid envelopes so 
customers could mail unused pharmaceu-
ticals back to the manufacturer. The bill 
passed Maine’s House of Representatives 
by a wide margin but was tabled in the 
state Senate in March 2010.  
In contrast to the United States, Europe 
has widespread standardized take-back pro-
grams. In the 2010 report Pharmaceuticals 
in the Environment: Results of an EEA 
Workshop, the European Environment 
Agency (EEA) stated most countries there 
collect  unused  drugs  separately  from 
household waste, usually at pharmacies 
(a handful also have separate collection 
sites alongside pharmacies). But even in 
Europe, not all unused pharmaceuticals are 
diverted from the waste stream. A survey 
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from Germany’s Management Strategies 
for Pharmaceutical Residues in Drinking 
Water (start) research program showed that 
consumers discarded 23% of liquid phar-
maceuticals prescribed and 7% of tablets. 
While some went into household trash, 
the proportion that went down the drain 
amounted to 364 tons of APIs flushed 
away every year. Only about a third of the 
population surveyed by the start program 
reported always returning their drugs to a 
pharmacy.
End of the Line
Daughton and Ruhoy have developed a 
methodology that could be used to quan-
tify unused pharmaceuticals that end up 
in the waste stream in the United States, 
using coroners’ records and other data 
sources. In the 15 December 2007 issue 
of Science of the Total Environment, they 
note that medical investigators from coro-
ners’ offices routinely search decedents’ 
homes for drugs in case they played a role 
in a death, and the coroner often main-
tains detailed records of the pharmaceuti-
cals found and their method of disposal. 
Creating a unified network of coroners’ 
databases from around the country could 
yield valuable insight into the types and 
amounts of pharmaceuticals consumers 
tend to accumulate.   
Researchers have also examined how 
to diminish environmental impacts of 
pharmaceuticals using the principles of 
green chemistry: Ruhoy says more man-
ufacturers have found ways to use less 
water or solvents and thereby lessen the 
environmental impacts of pharma  ceutical 
production. Still, few have rolled out 
products that might easily biodegrade in 
the environment. In the May 2003 issue 
of EHP, Daughton suggested expanding 
the use of “optically pure chiral drugs” to 
reduce by half—or sometimes more—the 
amount of API required in a medication. 
A chiral (or “handed”) molecule may have 
mirror-image configurations that are not 
quite identical; one form may be more 
effective by fitting into certain recep-
tors, whereas another may be ineffective 
or even harmful because of its different 
form. Focusing on the optimal configu-
ration of a molecule selects for materi-
als that can be used more efficiently by 
the human body while cutting down on 
pharmaceutical bulk.
Another  possibility  for  reducing 
the impact of APIs in the environment 
involves advising medical professionals 
about drugs that are less environmentally 
harmful. In Sweden the pharmaceuti-
cal industry has assisted the government 
in putting together a database of the 
possible environmental effects of various 
medications. A patient could select a less 
environmentally persistent painkiller, for 
example, by avoiding off-label use of the 
anticonvulsant carbamazepine. Europe is 
currently examining how to expand this 
Swedish Environmental Classification of 
Pharmaceuticals database to the interna-
tional level.
Daughton points out that reduced 
usage, lower dosages for personalized 
medicines tailored to an individual’s 
genome, and other approaches could cut 
down on human excretion of drugs to the 
environment—and the need to dispose of 
unused pharmaceuticals—while perhaps 
achieving better health care outcomes. 
“One of the downsides of focusing on 
drug disposal is that it serves to distract 
from the issues that could potentially 
have much more impact on the occur-
rence of APIs in the environment,” he 
comments. “This is especially true given 
that we don’t even know the relative con-
tributions of APIs in the environment 
that result from disposal versus intended 
usage.” 
Although the question of whether phar-
maceutical take-back programs make a dif-
ference does not yet have a clear answer, 
Kolpin remains optimistic about the pos-
sibilities for keeping pharmaceuticals out 
of the environment, observing that “more 
and more people [are] working on the 
issue . . . and providing results that advance 
the science.” He says that although it may 
be unrealistic to eliminate every contami-
nant from waste, perhaps researchers and 
regulators could focus on the “bad actors,” 
those compounds known to be the most 
common or most harmful. Some argue that 
consumers could have the most impact on 
the amount of pharmaceuticals in the envi-
ronment, for example in choosing to buy 
fewer or “greener” pharmaceuticals. 
Meanwhile, Maine’s LD 821 bill may 
yet see another day. Pistell says the bill 
will be reintroduced in January 2011 by 
a new sponsor, and that it will go to a 
natural resources committee—which is 
more familiar with product stewardship 
issues—instead of one on public health. 
The state already has refined the bill after 
hearing legislators’ concerns, according 
to Pistell, who explains, “lots of bills take 
several years to get through.” She adds, 
“Those who have greatest influence over 
a product—usually manufacturers—
certainly should have a role in dealing 
responsibly with a product at the end of 
its life.”
Naomi Lubick is a freelance science writer based in 
Zürich, Switzerland, and Folsom, CA. She has written for 
Environmental Science & Technology, Nature, and Earth.
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One 
of the downsides of focusing on drug disposal is 
that it serves to distract from the issues that could 
potentially have much more impact on the occurrence of APIs in 
the environment. This is especially true given that we don’t even 
know the relative contributions of APIs in the environment that 
result from disposal versus intended usage.
—Christian Daughton
U.S. Environmental Protection Agency
For More Information
National Programs and Institutes (a list of take-back programs and other resources in various states)
Teleosis Institute
http://www.teleosis.org/gpp-national.php
The Drug Take-Back Network News (recent news about drug take-back issues)
Product Stewardship Institute
http://www.takebacknetwork.com/news_t.php  
Swedish Environmental Classification of Pharmaceuticals
Swedish Association of the Pharmaceutical Industry
http://www.fass.se/LIF/miljo_splash/index_en.jsp